Increased Prevalence of Esophageal Eosinophilia in Patients with Inflammatory Bowel Disease.
Eosinophilic esophagitis
Epidemiology
Inflammatory bowel disease
Prevalence
Journal
Inflammatory intestinal diseases
ISSN: 2296-9365
Titre abrégé: Inflamm Intest Dis
Pays: Switzerland
ID NLM: 101677990
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
12
12
2018
accepted:
19
01
2019
entrez:
22
5
2019
pubmed:
22
5
2019
medline:
22
5
2019
Statut:
ppublish
Résumé
The overlap between eosinophilic esophagitis (EoE) and inflammatory bowel disease (IBD) has not been extensively examined. We aimed to assess the prevalence of esophageal eosinophilia in patients with IBD. We conducted a retrospective cohort study using diagnostic codes to identify adults with EoE and IBD between 2008 and 2016 at a tertiary care center. Electronic medical records were reviewed to extract clinical, endoscopic, and treatment data. Patients with esophageal eosinophilia and IBD were compared to EoE cases without IBD. Of 621 EoE patients and 4,814 IBD patients identified, 35 had a code for both diseases and 12 were confirmed to have overlapping IBD and esophageal eosinophilia. The prevalence of esophageal eosinophilia in IBD was 12/4814 (0.25%), and the prevalence of confirmed EoE in IBD was 5/4,814 (0.10%). There were no substantial clinical, endoscopic, or histologic differences between EoE patients with and without IBD. IBD was diagnosed before esophageal eosinophilia 92% of the time, with an average time between diagnoses of 9.6 years. Of the IBD patients, 71% were started on biologic anti-tumor necrosis factor-α therapy an average of 7.6 years prior to developing esophageal eosinophilia. The prevalence of esophageal eosinophilia in IBD is 5 times higher than expected in the general population (0.25 vs. 0.05%) and EoE in IBD is 2 times higher than expected (0.10 vs. 0.05%). Upper gastrointestinal (GI) symptoms in patients with IBD should merit evaluation not only for upper GI Crohn's disease, but also for esophageal eosinophilia.
Sections du résumé
BACKGROUND
BACKGROUND
The overlap between eosinophilic esophagitis (EoE) and inflammatory bowel disease (IBD) has not been extensively examined. We aimed to assess the prevalence of esophageal eosinophilia in patients with IBD.
METHODS
METHODS
We conducted a retrospective cohort study using diagnostic codes to identify adults with EoE and IBD between 2008 and 2016 at a tertiary care center. Electronic medical records were reviewed to extract clinical, endoscopic, and treatment data. Patients with esophageal eosinophilia and IBD were compared to EoE cases without IBD.
RESULTS
RESULTS
Of 621 EoE patients and 4,814 IBD patients identified, 35 had a code for both diseases and 12 were confirmed to have overlapping IBD and esophageal eosinophilia. The prevalence of esophageal eosinophilia in IBD was 12/4814 (0.25%), and the prevalence of confirmed EoE in IBD was 5/4,814 (0.10%). There were no substantial clinical, endoscopic, or histologic differences between EoE patients with and without IBD. IBD was diagnosed before esophageal eosinophilia 92% of the time, with an average time between diagnoses of 9.6 years. Of the IBD patients, 71% were started on biologic anti-tumor necrosis factor-α therapy an average of 7.6 years prior to developing esophageal eosinophilia.
CONCLUSIONS
CONCLUSIONS
The prevalence of esophageal eosinophilia in IBD is 5 times higher than expected in the general population (0.25 vs. 0.05%) and EoE in IBD is 2 times higher than expected (0.10 vs. 0.05%). Upper gastrointestinal (GI) symptoms in patients with IBD should merit evaluation not only for upper GI Crohn's disease, but also for esophageal eosinophilia.
Identifiants
pubmed: 31111034
doi: 10.1159/000497236
pii: iid-0003-0180
pmc: PMC6501545
doi:
Types de publication
Journal Article
Langues
eng
Pagination
180-186Références
Gastroenterology. 1999 Nov;117(5):1089-97
pubmed: 10535871
J Allergy Clin Immunol. 2001 Dec;108(6):954-61
pubmed: 11742273
Eur J Gastroenterol Hepatol. 2007 Oct;19(10):865-9
pubmed: 17873610
Clin Gastroenterol Hepatol. 2007 Dec;5(12):1424-9
pubmed: 17904915
Gastroenterology. 2007 Oct;133(4):1342-63
pubmed: 17919504
Best Pract Res Clin Gastroenterol. 2008;22(3):537-49
pubmed: 18492570
J Allergy Clin Immunol. 2008 Aug;122(2):425-7
pubmed: 18678345
Am J Gastroenterol. 2009 Mar;104(3):794-5
pubmed: 19209162
Gut. 2010 Jan;59(1):21-30
pubmed: 19828470
J Allergy Clin Immunol. 2011 Jul;128(1):3-20.e6; quiz 21-2
pubmed: 21477849
J Pediatr Gastroenterol Nutr. 2011 Aug;53(2):213-5
pubmed: 21788765
Gastroenterology. 2011 Nov;141(5):1593-604
pubmed: 21835135
J Innate Immun. 2011;3(6):594-604
pubmed: 21921589
J Allergy Clin Immunol. 2012 Feb;129(2):456-63, 463.e1-3
pubmed: 22206777
Am J Gastroenterol. 2013 May;108(5):679-92; quiz 693
pubmed: 23567357
Gastroenterology. 2013 Dec;145(6):1230-6.e1-2
pubmed: 23954315
Clin Gastroenterol Hepatol. 2014 Apr;12(4):589-96.e1
pubmed: 24035773
J Crohns Colitis. 2014 May;8(5):341-8
pubmed: 24094598
Gastrointest Endosc. 2014 Apr;79(4):577-85.e4
pubmed: 24275329
J Clin Gastroenterol. 2016 Feb;50(2):134-40
pubmed: 25710524
J Gastroenterol. 2015 May;50(5):495-507
pubmed: 25808229
Immunol Allergy Clin North Am. 2015 Aug;35(3):413-37
pubmed: 26209893
J Pediatr Gastroenterol Nutr. 2016 Apr;62(4):573-6
pubmed: 26308316
Am J Gastroenterol. 2016 Jul;111(7):926-32
pubmed: 27215923
Dig Dis Sci. 2016 Oct;61(10):2928-2934
pubmed: 27250980
Gastroenterology. 2018 Jan;154(2):319-332.e3
pubmed: 28774845
United European Gastroenterol J. 2017 Oct;5(6):762-772
pubmed: 29026590
Am J Gastroenterol. 2017 Dec;112(12):1849-1858
pubmed: 29112200
Clin Rev Allergy Immunol. 2018 Aug;55(1):88-98
pubmed: 29234969
J Clin Gastroenterol. 1988 Jun;10(3):286-97
pubmed: 2980764
Ann Allergy Asthma Immunol. 2018 Dec;121(6):711-716
pubmed: 30194971
Gastroenterology. 2019 Feb;156(3):592-603.e10
pubmed: 30395812